Search results for "Immunization"

showing 10 items of 313 documents

MMR and MMRV vaccines.

2018

Measles, mumps, rubella and varicella are viral infections which can implicate seriously long-term sequelae of infected individuals or even the unborn child. Vaccines against the individual diseases have long been available. Global measles vaccination is estimated to have prevented more than 20million deaths during 2000-2015. During the same time period, measles incidence decreased from 146 to 36 cases per million populations. Today vaccinations against measles, mumps, rubella and varicella are now carried out mainly with combination vaccines. These are today known as immunogenic and safe. MMRV had similar immunogenicity and overall safety profiles to MMR administered with or without varice…

Varicella vaccineRubellaMeasles03 medical and health sciences0302 clinical medicineChickenpox030225 pediatricsmedicineHumans030212 general & internal medicineAdverse effectMumpsRubellaVaccinesGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityIncidence (epidemiology)VaccinationPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicinebusinessMeaslesVaccine
researchProduct

Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

2014

Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and produ…

Viral MyocarditisvirusesIon chromatographyGenetic VectorsCoxsackievirus InfectionsBiologyAntibodies ViralVirus03 medical and health sciencesMice0302 clinical medicineImmune systemVirus-like particleAntibody SpecificityVirologyGene OrderAnimalscardiovascular diseases030212 general & internal medicineVaccines Virus-Like Particle030304 developmental biologyPharmacology0303 health sciencesImmunity Cellularta1182virus diseasesmusculoskeletal systemChromatography Ion ExchangeVirology3. Good healthEnterovirus B HumanVaccinationDisease Models AnimalImmunizationCoxsackievirus b3cardiovascular systemFemaleImmunizationBaculoviridaeAntiviral Research
researchProduct

Booster vaccination after neonatal priming with acellular pertussis vaccine.

2010

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct

A combined proteomic and immunologic approach for the analysis of Schistosoma mansoni cercariae and adult worm protein extracts and the detection of …

2011

International audience; Understanding the mode of Schistosoma mansoni larval invasion and the mechanism of immune evasion utilized by larvae and adult worms is essential for a rational development of vaccines or drugs to prevent or cure the disease. This parasite has a very complex molecular organization in all parasite stages, and identifying the major parasite proteins would give clues to schistosome metabolism and to the interaction of the parasite with the host immune system. Our goal was the evaluation of the protein parasite repertoire using a proteomic approach, and the characterization of protein extracts from two different parasite stages of a Venezuelan isolate, such as cercariae …

[SDE] Environmental SciencesIDENTIFICATIONproteome[SDV]Life Sciences [q-bio]ANTIGENPROTECTIVE IMMUNITYIMMUNOGENICITYSm28GSTIMMUNIZATIONVIABILITYSECRETIONS[SDV] Life Sciences [q-bio]GLUTATHIONE-S-TRANSFERASEEXPERIMENTAL-INFECTIONparasitic diseasesSYNTHETIC PEPTIDES[SDE]Environmental SciencesSchistosoma[SDV.BV]Life Sciences [q-bio]/Vegetal Biology[SDV.BV] Life Sciences [q-bio]/Vegetal Biology
researchProduct

Effects of adjuvants of the cholera toxin family on CD4 + T cell responses in a murine model of intrarectal immunization with rotavirus-like particles

2011

Mucosal immunization is an important goal of vaccine development to protect against pathogens that use mucosa as portals of entry. However, the use of non-replicating antigens requires the addition of adjuvants.Cholera-like enterotoxins, cholera toxin (CT) from Vibrio cholerae and the heat-labile enterotoxin (LT) from toxinogenic strains of E. coli, as well as the mutant LR-192G and their B subunits (CTB and LTB) have been shown to increase immune responses against unrelated co-administered antigens by mucosal routes. However, their mechanism of action is very complex and not completely understood and differences exist between holotoxins and B subunits and within molecules, differences exis…

[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyIL-2Cholera toxinLT-R192GVaccination muqueuseMucosal immunizationCD4 T lymphocyteE. coli heat-labile enterotoxinB subunitFoxp3[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyLymphocyte T CD4Lymphocyte T régulateurSous-unité BEntérotoxine thermolabile d’E. coliRegulatory T cell[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciencesAdjuvantToxine du choléra
researchProduct

The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis.

2017

Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-…

allergic rhinitisPyroglyphidaenew allergen sensitizationasthmameta-analysiDesensitization ImmunologicAnti-Allergic Agentsallergen immunotherapyHypersensitivityAnimalsHumansImmunizationAntigens DermatophagoidesChildRandomized Controlled Trials as TopicInternational forum of allergyrhinology
researchProduct

Mapping routine measles vaccination in low- and middle-income countries

2021

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here we generated annual estimates of routine childhoo…

and promotion of well-beingVacunación MasivaInternationalityDisease preventionchildren under 5 years oldGeographic MappingRural Healthmedicine.disease_causeCross-reactivity0302 clinical medicineRA0421Vaccination Refusal030212 general & internal medicineChildimmunity patternsPediatric0303 health sciencesPublic healthMultidisciplinarybiologyVaccinationUncertaintyIMMUNIZATION3142 Public health care science environmental and occupational healthCOVERAGE3. Good healthTIME3.4 VaccinesChild PreschoolInfectious diseasesA990 Medicine and Dentistry not elsewhere classifiedAntibodyEngineering sciences. TechnologyAFRICAGeneral Science & TechnologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease prevention ; COVID-19 ; Public health ; Infectious diseases610 Medicine & healthGlobal Vaccine Action Plan (GVAP)Local Burden of Disease Vaccine Coverage CollaboratorsArticleVaccine Related03 medical and health sciencesmeasles vaccineMeasels ; Vaccination ; Low- and middle-income countries ; Local burden of disease ; Public healthClinical ResearchmedicineHumansHealthcare DisparitiesPreschoolPROGRESS030304 developmental biologybusiness.industryMORTALITYDeveloped CountriesPreventionCommentVacunaciónUrban HealthCOVID-19Prevention of disease and conditionsVirologyCoronavirusGood Health and Well BeingCobertura de Vacunaciónbiology.proteinImmunizationbusinessMeasles
researchProduct

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

2020

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical development are traditional inactivated or live attenuated vaccines. Even though these vaccines work well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles (VLPs), can offer important advantages in the manufacturing and epitope engineering. We have previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production of CVB3-VLPs with enhanced pro…

and promotion of well-beingvirusesPROTECTS MICEPOLIOVIRUSCardiovascularcomplex mixturesvirus-like particle (VLP)virus-like particleVaccine RelatedvaccineIMMUNE-RESPONSECoxsackievirus B (CVB)COXSACKIEVIRUS B3lcsh:QH301-705.5PARTICLE VACCINE11832 Microbiology and virologyPreventionrokotteetvirus diseasesMICROSCOPYPrevention of disease and conditionsenteroviruksetHeart DiseaseInfectious DiseasesGood Health and Well Beinglcsh:Biology (General)3.4 VaccinesCoxsackievirus BENTEROVIRUS 71VIRUSImmunization3111 BiomedicineInfectionRECEPTOR-BINDINGB1Biotechnology
researchProduct

Molecular mechanisms of primary and secondary mucosal immunity using avian infectious bronchitis virus as a model system

2007

Although mucosal immune responses are critical for protection of hosts from clinical illness and even mortality caused by mucosal pathogens, the molecular mechanism of mucosal immunity, which is independent of systemic immunity, remains elusive. To explore the mechanistic basis of mucosal protective immunity, gene transcriptional profiling in mucosal tissues was evaluated after the primary and secondary immunization of animals with an attenuated avian infectious bronchitis virus (IBV), a prototype of Coronavirus and a well-characterized mucosal pathogen. Results showed that a number of innate immune factors including toll-like receptors (TLRs), retinoic-acid-inducible gene-1 (RIG-1), type I…

animal diseasesRespiratory Tract DiseasesLymphocyte Activationmedicine.disease_causeDC dendritic cellMucosal immunityCXCR chemokine (C-X-C motif) receptorCCR chemokine (C-C motif) receptorOligonucleotide Array Sequence AnalysisCoronavirusbiologyReverse Transcriptase Polymerase Chain ReactionAcquired immune systemSpecific Pathogen-Free OrganismsCytokinesAntibodyAvian infectious bronchitis virusCoronavirus InfectionsIBV infectious bronchitis virusInfectious bronchitis virusImmunologychemical and pharmacologic phenomenaArticlePrimary and secondary immunityMolecular mechanismIBVTranscriptional regulationImmune systemImmunitymedicineAnimalsIFN interferonTLR toll-like receptorImmunity MucosalPoultry DiseasesInnate immune systemGeneral VeterinaryGene Expression ProfilingComplement System ProteinsTh1 Cellsbiochemical phenomena metabolism and nutritionCTL cytotoxic T lymphocytebiology.organism_classificationIg immunoglobulinIL interleukinMucosal immunologyImmunologybiology.proteinRNAbacteriaImmunizationChickensVeterinary Immunology and Immunopathology
researchProduct

Immunization of rainbow trout, Oncorhynchus mykiss (Walbaum), with a low molecular mass fraction isolated from Flavobacterium psychrophilum.

2008

Flavobacterium psychrophilum, the causative agent of rainbow trout fry syndrome has become a widespread fish pathogen in freshwater aquaculture worldwide. In this study, a low molecular mass fraction (P25-33), with an approximate weight of 25-33 kDa, was identified among F. psychrophilum strains in an immunoblotting analysis with anti-F. psychrophilum sera. The immunogenic efficacy of the isolated and extracted P25-33 was investigated in two intraperitoneal immunization trials with rainbow trout, Oncorhynchus mykiss (Walbaum). The first trial included immunizations using P25-33 with Freund's complete adjuvant (FCA) and the second trial included immunizations using P25-33, formalin-inactivat…

animal structuresanimal diseasesVeterinary (miscellaneous)medicine.medical_treatmentFreund's AdjuvantImmunoblottingFlavobacterium psychrophilumEnzyme-Linked Immunosorbent AssayAquatic ScienceBiologyFlavobacteriumMicrobiologyFish DiseasesImmune systemFlavobacteriaceae InfectionsmedicineAnimalsPathogenMolecular massAntibodies BacterialImmunizationOncorhynchus mykissBacterial Vaccinesbiology.proteinRainbow troutImmunizationAntibodyAdjuvantJournal of fish diseases
researchProduct